Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. The company is leveraging the ability of concentrated, locally delivered antimicrobials to treat the bacterial biofilms typically responsible for musculoskeletal infections while minimizing off-target tissue exposure and associated adverse effects. Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local delivery. The company's lead candidate, VT-X7, is in Phase 2 development to treat chronic periprosthetic joint infections, a serious complication of joint replacement surgery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/08/22 | $30,000,000 | Series B |
HM Capital Johnson & Johnson Development Corporation (JJDC) Medvest Capital | undisclosed |
| 09/21/23 | $23,000,000 | Series C |
Asteroid Partners Gideon Strategic Partners HM Capital Johnson & Johnson Development Corporation (JJDC) Medvest Capital Prism Ventures | undisclosed |
